Related Experiment Video
Updated: Sep 24, 2026

A Standard Methodology to Examine On-site Mutagenicity As a Function of Point Mutation Repair Catalyzed by CRISPR/Cas9 and SsODN in Human Cells
Published on: August 25, 2017
Therapeutic oligonucleotides as genetic medicines: The current state and future perspective
Bruno Miguel Da Cruz Godinho1, Chantal M Ferguson2, Annemieke Aartsma-Rus3
1Board of Directors, Oligonucleotide Therapeutics Society, San Diego, CA, USA.
Abstract:
Antisense therapeutic oligonucleotides are entering a transformative era in clinical development, with a total of 21 oligonucleotides approved and a robust pipeline poised for the coming years. These drugs have emerged as a cornerstone of genetic medicine, providing a programmable platform to modulate gene expression and treat otherwise untreatable disorders. This review covers the different mechanisms of action of these drugs and highlights the key advances in oligonucleotide chemistry and delivery that have supported the clinical successes witnessed in the last decade. It also provides a historical account and overview of the growing number of approvals and key phase 3 studies. Finally, it offers a perspective on the future of the field, initially focused only on rare diseases and now expanding to common disorders.
Related Concept Videos
Gene Therapy
Gene Therapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenomics: Identification of New Drug Targets
Microorganisms in Medicine and Therapeutics

